CompletedNCT01458340
Parallel, Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Medication studyAges 18–45United States
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- Bradenton and 16 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 295
- Sponsor
- Theravance Biopharma
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT01458340
- Official title
Show the full official title
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Get this study by email
Recruitment & locations
CompletedBradenton · Jacksonville · Maitland
13 more locations
- Palm Beach
- Smyrna
- Overland Park
- Saint Charles
- Las Vegas
- New York
- Oklahoma City
- Portland
- Lincoln
- Memphis
- Austin
- Salt Lake City
- Seattle
Questions about this study
Who is behind this study?
The study sponsor is Theravance Biopharma.
Did this study involve medication?
Yes. The study involved medication, including TD-9855 and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)